NCT07155954 Value of Super-resolution Ultrasonography in Differentiating Benign and Malignant Lymph Nodes
| NCT ID | NCT07155954 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Peking University Third Hospital |
| Condition | Lymphadenopathy |
| Study Type | OBSERVATIONAL |
| Enrollment | 779 participants |
| Start Date | 2024-10-23 |
| Primary Completion | 2027-10-22 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 779 participants in total. It began in 2024-10-23 with a primary completion date of 2027-10-22.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Lymph nodes are one of the most important components of the human immune system, and superficial lymph node enlargement lacks specificity. Ultrasound examination has been widely used in the diagnosis of lymph node lesions and is of great significance in distinguishing between benign and malignant. However, the two-dimensional and Doppler ultrasound features of different types of lymph node lesions overlap and intersect, and the blood flow perfusion information of lymph nodes can provide more information for differentiation. At present, the widely used contrast-enhanced ultrasound is easier to evaluate blood flow perfusion and can display small blood vessels smaller than 100 microns. The diagnostic accuracy of cervical lymph nodes using contrast-enhanced ultrasound is 80-90%. However, current contrast-enhanced ultrasound is limited by physical diffraction, with a resolution ranging from sub-millimeter to millimeter. This limitation hinders the visualization of small blood vessels or microcirculation by ultrasound, and parameters such as vascular size, spatial vascular pattern, and velocity of microcirculation are crucial for disease diagnosis and prognosis evaluation. Super resolution ultrasound (SRUS) is a new blood flow imaging technique. By tracking the movement trajectory of micro-bubbles instead of imaging the micro-bubbles themselves, the ultrasound diffraction limit can be exceeded to improve the sensitivity and image resolution of blood flow. Thus the study aim to evaluate the feasibility of SRUS technology in distinguishing between benign and malignant lymph nodes, and compare the differences in blood flow distribution and perfusion index between benign and malignant lymph nodes under SRUS imaging.
Eligibility Criteria
Inclusion Criteria: * (1)suggested abnormal lymph nodes indicated by ultrasonography; (2) Patients scheduled for lymph nodes puncture or fine needle aspiration or surgery; (3) Age greater than or equal to 18 years old. Exclusion Criteria: * (1) Pregnant and lactating women; (2)pathological results not indicating benign or malignant lymph nodes; (3) history of chemotherapy or radiotherapy ; (4) History of allergies to eggs, milk, and ultrasound contrast agents; (5) Patients with acute coronary syndrome, severe pulmonary hypertension, or acute respiratory distress syndrome.
Contact & Investigator
li g cui, Chief Physician
STUDY CHAIR
Peking University Third Hospital
Frequently Asked Questions
Who can join the NCT07155954 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphadenopathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07155954 currently recruiting?
Yes, NCT07155954 is actively recruiting participants. Contact the research team at cuijuegang@126.com for enrollment information.
Where is the NCT07155954 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT07155954 clinical trial?
NCT07155954 is sponsored by Peking University Third Hospital. The principal investigator is li g cui, Chief Physician at Peking University Third Hospital. The trial plans to enroll 779 participants.